Search for other papers by Qi Zhang in
Google Scholar
PubMed
Search for other papers by Hongshan Wang in
Google Scholar
PubMed
Search for other papers by Yanhong Xie in
Google Scholar
PubMed
Search for other papers by Suming Huang in
Google Scholar
PubMed
Search for other papers by Ke Chen in
Google Scholar
PubMed
Search for other papers by Botian Ye in
Google Scholar
PubMed
Search for other papers by Yupeng Yang in
Google Scholar
PubMed
Search for other papers by Jie Sun in
Google Scholar
PubMed
Search for other papers by Hongyong He in
Google Scholar
PubMed
Search for other papers by Fenglin Liu in
Google Scholar
PubMed
Search for other papers by Zhenbin Shen in
Google Scholar
PubMed
Search for other papers by Weidong Chen in
Google Scholar
PubMed
Search for other papers by Kuntang Shen in
Google Scholar
PubMed
Search for other papers by Yuan Ji in
Google Scholar
PubMed
Search for other papers by Yihong Sun in
Google Scholar
PubMed
A new subcategory, grade 3 neuroendocrine tumors, is incorporated into the grading system of pancreatic neuroendocrine neoplasms in the 2017 WHO classification in order to differentiate grade 3 neuroendocrine tumors from neuroendocrine carcinomas. The 2019 WHO classification extends the concept of grade 3 neuroendocrine tumors to gastrointestinal high-grade neuroendocrine neoplasms. However, there is still limited study focusing on the gastric grade 3 neuroendocrine tumors and gastric neuroendocrine carcinomas. We retrospectively enrolled 151 gastric high-grade neuroendocrine neoplasms patients, who underwent radical resection from January 2007 to December 2015. Clinicopathologic and prognostic features were studied. The Surveillance, Epidemiology, and End Results (SEER) database was used to verify the prognostic determinants found in the Zhongshan cohort. Neuroendocrine carcinomas showed a higher Ki67 index and higher mitotic count than grade 3 neuroendocrine tumors. We identified 109 (72.2%) patients with neuroendocrine carcinomas, 12 (7.9%) patients with grade 3 neuroendocrine tumors, and 30 (19.9%) patients with mixed neuroendocrine-non-neuroendocrine neoplasms. Although neuroendocrine carcinomas demonstrated higher Ki67 index (P = 0.004) and mitoses (P = 0.001) than grade 3 neuroendocrine tumors, their prognosis after radical resection did not demonstrate significant differences (P = 0.709). Tumor size, perineural invasion, and TNM stage were independent prognostic factors of gastric high-grade neuroendocrine neoplasms.
Search for other papers by Hanbaro Kim in
Google Scholar
PubMed
Search for other papers by Ki Byung Song in
Google Scholar
PubMed
Search for other papers by Dae Wook Hwang in
Google Scholar
PubMed
Search for other papers by Jae Hoon Lee in
Google Scholar
PubMed
Search for other papers by Shadi Alshammary in
Google Scholar
PubMed
Search for other papers by Song Cheol Kim in
Google Scholar
PubMed
portal vein invasion also underwent portal vein resection. Our center has the following polices for surgical resection of PNETs: (1) F-PNETs are surgically resected; (2) for NF-PNETs in the body and tail, tumors less than 1 cm are observed and tumors
Search for other papers by Logan Mills in
Google Scholar
PubMed
Search for other papers by Panagiotis Drymousis in
Google Scholar
PubMed
Search for other papers by Yogesh Vashist in
Google Scholar
PubMed
Search for other papers by Christoph Burdelski in
Google Scholar
PubMed
Search for other papers by Andreas Prachalias in
Google Scholar
PubMed
Search for other papers by Parthi Srinivasan in
Google Scholar
PubMed
Search for other papers by Krishna Menon in
Google Scholar
PubMed
Search for other papers by Corina Cotoi in
Google Scholar
PubMed
Search for other papers by Saboor Khan in
Google Scholar
PubMed
Search for other papers by Judith Cave in
Google Scholar
PubMed
Search for other papers by Thomas Armstrong in
Google Scholar
PubMed
Search for other papers by Martin O Weickert in
Google Scholar
PubMed
Search for other papers by Jakob Izbicki in
Google Scholar
PubMed
Search for other papers by Joerg Schrader in
Google Scholar
PubMed
Search for other papers by Andreja Frilling in
Google Scholar
PubMed
Search for other papers by John K Ramage in
Google Scholar
PubMed
Search for other papers by Raj Srirajaskanthan in
Google Scholar
PubMed
Small non-functioning pancreatic NETs (pNETs) ≤2 cm can pose a management dilemma in terms of surveillance or resection. There is evidence to suggest that a surveillance approach can be considered since there are no significant radiological changes observed in lesions during long-term follow-up. However, other studies have suggested loco-regional spread can be present in ≤2 cm pNETs. The aim of this study was to characterise the prevalence of malignant features and identify any useful predictive variables in a surgically resected cohort of pNETs. 418 patients with pNETs were identified from 5 NET centres. Of these 227 were included for main analysis of tumour characteristics. Mean age of patients was 57 years, 47% were female. The median follow-up was 48.2 months. Malignant features were identified in 38% of ≤2 cm pNETs. ROC analysis showed that the current cut-off of 20 mm had a sensitivity of 84% for malignancy. The rate of malignant features is in keeping with other surgical series and challenges the belief that small pNETs have a low malignant potential. This study does not support a 20 mm size cut-off as being a solitary safe parameter to exclude malignancy in pNETs.
Department of Tumor and Diagnostic Pathology, Atomic Bomb Disease Institute, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
Search for other papers by Ayako Sato in
Google Scholar
PubMed
Search for other papers by Katsuya Matsuda in
Google Scholar
PubMed
Search for other papers by Takahiro Motoyama in
Google Scholar
PubMed
Al-Farabi Kazakh National University, Almaty City, Republic of Kazakhstan
Search for other papers by Zhanna Mussazhanova in
Google Scholar
PubMed
Search for other papers by Ryota Otsubo in
Google Scholar
PubMed
Search for other papers by Hisayoshi Kondo in
Google Scholar
PubMed
Search for other papers by Yuko Akazawa in
Google Scholar
PubMed
Search for other papers by Miyoko Higuchi in
Google Scholar
PubMed
Search for other papers by Ayana Suzuki in
Google Scholar
PubMed
Search for other papers by Mitsuyoshi Hirokawa in
Google Scholar
PubMed
Search for other papers by Akira Miyauchi in
Google Scholar
PubMed
Search for other papers by Takeshi Nagayasu in
Google Scholar
PubMed
Search for other papers by Masahiro Nakashima in
Google Scholar
PubMed
the subjects declined to join in this study. All cytology samples were obtained from surgically resected thyroid glands by FNAC, and sent to the Department of Tumor and Diagnostic Pathology, Nagasaki University. Final diagnosis of all cases was
Centre for Endocrinology, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK
Search for other papers by Nicola Tufton in
Google Scholar
PubMed
Department of Paediatric Endocrinology, Royal London Hospital, Barts Health NHS Trust, London, UK
Search for other papers by Lucy Shapiro in
Google Scholar
PubMed
Search for other papers by Anju Sahdev in
Google Scholar
PubMed
Search for other papers by Ajith V Kumar in
Google Scholar
PubMed
Search for other papers by Lee Martin in
Google Scholar
PubMed
Centre for Endocrinology, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK
Search for other papers by William M Drake in
Google Scholar
PubMed
Centre for Endocrinology, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK
Search for other papers by Scott A Akker in
Google Scholar
PubMed
Department of Paediatric Endocrinology, Royal London Hospital, Barts Health NHS Trust, London, UK
Search for other papers by Helen L Storr in
Google Scholar
PubMed
– non avid 27 Abdo PGL Died aged 31 years 13 24 Index c.311delAinsGG exon 4 M 12 Abdo PGL (1991) 70 VMA negative a Surgically resected No further disease – 25 years since diagnosis 21 13
Search for other papers by Erik Rösner in
Google Scholar
PubMed
Search for other papers by Daniel Kaemmerer in
Google Scholar
PubMed
Search for other papers by Elisa Neubauer in
Google Scholar
PubMed
Search for other papers by Jörg Sänger in
Google Scholar
PubMed
Search for other papers by Amelie Lupp in
Google Scholar
PubMed
commonly used anti-PD-L1 antibodies. Materials and methods Tumour specimens The pilot study was conducted using a panel of 43 formalin-fixed, paraffin-embedded surgically resected tumour samples from 43 patients diagnosed with either
Fuzong Clinical Medical College of Fujian Medical University, Fuzhou, China
Search for other papers by Tao Mei in
Google Scholar
PubMed
Search for other papers by Jianhe Zhang in
Google Scholar
PubMed
Search for other papers by Liangfeng Wei in
Google Scholar
PubMed
Search for other papers by Xingfeng Qi in
Google Scholar
PubMed
Search for other papers by Yiming Ma in
Google Scholar
PubMed
Search for other papers by Xianhua Liu in
Google Scholar
PubMed
Search for other papers by Shaohua Chen in
Google Scholar
PubMed
Search for other papers by Songyuan Li in
Google Scholar
PubMed
Search for other papers by Jianwu Wu in
Google Scholar
PubMed
Search for other papers by Shousen Wang in
Google Scholar
PubMed
surgically resected PA tumor samples that were pathologically confirmed were collected from January 2013 to April 2017 at the Department of Neurosurgery of Fuzhou General Hospital. Complete medical records, images and pathological specimens were obtained (in
Search for other papers by Chao-bin He in
Google Scholar
PubMed
Search for other papers by Yu Zhang in
Google Scholar
PubMed
Search for other papers by Zhi-yuan Cai in
Google Scholar
PubMed
Search for other papers by Xiao-jun Lin in
Google Scholar
PubMed
-specific survival in patients with surgically resected pancreatic head adenocarcinoma: a competing risk nomogram analysis . Journal of Cancer 2018 9 3156 – 3167 . ( https://doi.org/10.7150/jca.25494 ) 30210639 10.7150/jca.25494 19 He C Mao Y Wang J Duan F
Search for other papers by Ruth Therese Casey in
Google Scholar
PubMed
Search for other papers by Deborah Saunders in
Google Scholar
PubMed
Search for other papers by Benjamin George Challis in
Google Scholar
PubMed
Search for other papers by Deborah Pitfield in
Google Scholar
PubMed
Search for other papers by Heok Cheow in
Google Scholar
PubMed
Search for other papers by Ashley Shaw in
Google Scholar
PubMed
Search for other papers by Helen Lisa Simpson in
Google Scholar
PubMed
the management of secretory and non-functioning PNETS ( 4 ) and recommend 6–9 monthly CT or MRI for non-functioning PNETS <2 cm; and monitoring of patients with surgically resected tumours (grade 1–2) every 3–6 months with either modality. Recent
Wolfson Diabetes and Endocrine Centre, Addenbrooke’s Hospital, Cambridge, UK
IMED Biotech Unit, Clinical Discovery Unit, AstraZeneca, UK
Search for other papers by Benjamin G Challis in
Google Scholar
PubMed
Wolfson Diabetes and Endocrine Centre, Addenbrooke’s Hospital, Cambridge, UK
Search for other papers by Andrew S Powlson in
Google Scholar
PubMed
Search for other papers by Ruth T Casey in
Google Scholar
PubMed
Search for other papers by Carla Pearson in
Google Scholar
PubMed
Search for other papers by Brian Y Lam in
Google Scholar
PubMed
Search for other papers by Marcella Ma in
Google Scholar
PubMed
Search for other papers by Deborah Pitfield in
Google Scholar
PubMed
Search for other papers by Giles S H Yeo in
Google Scholar
PubMed
Search for other papers by Edmund Godfrey in
Google Scholar
PubMed
Department of Nuclear Medicine, Addenbrooke’s Hospital, Cambridge, UK
Search for other papers by Heok K Cheow in
Google Scholar
PubMed
Wolfson Diabetes and Endocrine Centre, Addenbrooke’s Hospital, Cambridge, UK
Search for other papers by V Krishna Chatterjee in
Google Scholar
PubMed
Search for other papers by Nicholas R Carroll in
Google Scholar
PubMed
Search for other papers by Ashley Shaw in
Google Scholar
PubMed
Department of Nuclear Medicine, Addenbrooke’s Hospital, Cambridge, UK
Search for other papers by John R Buscombe in
Google Scholar
PubMed
Search for other papers by Helen L Simpson in
Google Scholar
PubMed
accordance with published consensus guidelines ( 11 ), with no evidence of insulinoma recurrence (median follow-up: 75 months; range: 66–150). Insulinoma characteristics Of the surgically resected insulinoma, 3 tumours were identified within the